Prognostic value of serum IL-17 and VEGF levels in small cell lung cancer

被引:28
作者
Lin, Qunying [1 ]
Xue, Lei [2 ]
Tian, Tian [3 ,4 ]
Zhang, Bo [3 ,4 ,5 ]
Guo, Lijing [1 ]
Lin, Guosheng [1 ]
Chen, Zhiwei [1 ]
Fan, Kexing [3 ,4 ,5 ]
Gu, Xiaobin [3 ,4 ]
机构
[1] Putian Univ, Affiliated Hosp, Dept Resp Med, Putian, Fujian, Peoples R China
[2] Second Mil Med Univ, Changzheng Hosp, Dept Thorac Surg, Shanghai 200433, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Ctr Canc, Beijing 100853, Peoples R China
[4] Chinese PLA Med Sch, Beijing, Peoples R China
[5] Second Mil Med Univ, Int Joint Canc Inst, 800 Xiang Yin Rd,New Bldg West 10-11th Floor, Shanghai 200433, Peoples R China
基金
中国国家自然科学基金;
关键词
Interleukin-17; Prognosis; Small cell lung cancer; Vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; FOXP3; IL17;
D O I
10.5301/jbm.5000148
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Objective: To explore the prognostic value of serum interleukin-17 (IL-17) and vascular endothelial growth factor (VEGF) levels in patients with small cell lung cancer (SCLC). Materials and Methods: IL-17 and VEGF levels were determined by a commercially available ELISA method. Results: Serum IL-17 and VEGF levels were higher in the SCLC group than the control group (p<0.001 and p<0.0001, respectively). In addition, there was a significant correlation between IL-17 and VEGF. The level of IL-17 showed significant correlations with tumor stage and tumor metastasis, while serum VEGF levels were significantly associated only with tumor metastasis. Univariate and multivariate analysis indicated that an elevated IL-17 level was an independent prognostic factor for shorter overall survival in SCLC. Conclusions: IL-17 may play an important role in tumor dissemination in SCLC patients and measurement of IL-17 could have useful prognostic value for worse overall survival in patients with SCLC.
引用
收藏
页码:E359 / E363
页数:5
相关论文
共 21 条
[1]   Vascular endothelial growth factor and its relationship to inflammatory mediators [J].
Angelo, Laura S. ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2007, 13 (10) :2825-2830
[2]  
[Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590
[3]   An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy [J].
Chung, Alicia S. ;
Wu, Xiumin ;
Zhuang, Guanglei ;
Ngu, Hai ;
Kasman, Ian ;
Zhang, Jianhuan ;
Vernes, Jean-Michel ;
Jiang, Zhaoshi ;
Meng, Y. Gloria ;
Peale, Franklin V. ;
Ouyang, Wenjun ;
Ferrara, Napoleone .
NATURE MEDICINE, 2013, 19 (09) :1114-1123
[4]   TH 17 cells in development:: an updated view of their molecular identity and genetic programming [J].
Dong, Chen .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (05) :337-348
[5]   High IL-17-positive tumor immune cell infiltration is indicative for chemosensitivity of ovarian carcinoma [J].
Droeser, Raoul A. ;
Gueth, Uwe ;
Eppenberger-Castori, Serenella ;
Stadlmann, Sylvia ;
Hirt, Christian ;
Terracciano, Luigi ;
Singer, Gad .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (08) :1295-1302
[6]   Role of angiogenesis in tumor growth and metastasis [J].
Folkman, J .
SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18
[7]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[8]   Treatment of Small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [J].
Jett, James R. ;
Schild, Steven E. ;
Kesler, Kenneth A. ;
Kalemkerian, Gregory P. .
CHEST, 2013, 143 (05) :E400-E419
[9]   IL-17 and Th17 Cells [J].
Korn, Thomas ;
Bettelli, Estelle ;
Oukka, Mohamed ;
Kuchroo, Vijay K. .
ANNUAL REVIEW OF IMMUNOLOGY, 2009, 27 :485-517
[10]   High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas [J].
Le Gouvello, S. ;
Bastuji-Garin, S. ;
Aloulou, N. ;
Mansour, H. ;
Chaumette, M-T ;
Berrehar, F. ;
Seikour, A. ;
Charachon, A. ;
Karoui, M. ;
Leroy, K. ;
Farcet, J-P ;
Sobhani, I. .
GUT, 2008, 57 (06) :772-779